Answers are grounded in this paper and cite their sources.
Evaluates CD19 genetic variants' impact on CAR T-cell therapy in Mediterranean populations, suggesting personalized treatment approaches.
7008 Background: CAR T-cell therapy has transformed the treatment of B-cell malignancies. However, relapse due to CD19 antigen escape remain a major challenge, often driven by genetic variants affecting CD19 structure, leading to CAR-T resistance. Mediterranean populations including Arabs, remain underrepresented in genomic studies. The Arabian prevalence and functional impact of CD19 variants is unknown. Methods: We analyzed and annotated CD19 NGS data from a Mediterranean cohort comprised of 1,305 Arabian individuals. The overall allele frequencies were compared to global databases. Clinically reported resistance mutations were prioritized based on published CAR T-cell studies. Hardy-Weinberg Equilibrium (HWE) was also assessed. Results: This study characterizes functionally significant CD19 polymorphisms in a Mediterranean population, with particular focus on the clinically relevant L174V (rs2904880) variant known to associate with CAR-T therapy resistance. 174V was seen in this cohort with a Minor Allele Frequency (MAF) of 76.3%., and a variant allele homozygosity (V/V) of 65.2%. Conclusions: Our cohort displayed elevated V174 homozygosity compared to other populations, including Europeans, Americans, and South Asians, potentially predisposing to diminished CAR-T efficacy. These findings indorse population-adjusted CAR-T product development, and implementation of pre-therapy CD19 genotyping protocols to identify at-risk patients. Development of CARs targeting conserved CD19-epitopes, or combinatorial antigen approaches is warranted to mitigate resistance.
No takes yet. Share an insight, caveat, or question.
Alsmadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: